Navigation Links
Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
Date:1/25/2011

FRAZER, Pa., Jan. 25, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a phase IV clinical trial of NUVIGIL® (armodafinil) Tablets [C-IV] in patients experiencing excessive sleepiness associated with shift work disorder, specifically during the end of their night shifts (i.e., 4:00 a.m. to 8:00 a.m.), including the commute home.  The study data showed statistically significant difference in improvement in overall clinical condition related to late-shift sleepiness in patients receiving NUVIGIL compared to the placebo group.  This is the largest trial ever conducted in this patient population, with more than 380 patients randomized to treatment with NUVIGIL or placebo.

The primary outcome measure of this six-week, multicenter, double-blind study of NUVIGIL (150 mg) was the Clinical Global Impression of Change (CGI-C) scale.  The CGI-C in this study asked that the clinician rate the patient's improvement in overall clinical condition as it related to sleepiness with shift work disorder late in the shift.  Using this rating, the percentage of patients taking NUVIGIL who experienced improvement from baseline was 77 percent versus 57 percent for placebo (p<0.0001).  The key secondary outcome was measured using the Global Assessment of Functioning (GAF), a well-recognized assessment of patient functioning found in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Patients receiving NUVIGIL showed a 9.5 point improvement over baseline in the GAF versus a 5.2 point improvement in the placebo group (p< 0.0001).

The most frequently reported adverse events in this study are consistent with those described in the NUVIGIL prescribing information, and include headache, nausea, and insomnia.  There were no serious adverse events observed in pati
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Amgen (NASDAQ: AMGN ) announced ... per share dividend for the third quarter of 2014. ... to all stockholders of record as of the close ... About Amgen Amgen is committed to unlocking the potential ... discovering, developing, manufacturing and delivering innovative human therapeutics. This ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... Microdosing or Phase 0 clinical testing has ... phase of the drug development process in the ... providers in preclinical testing and technology dependence is ... alliances, fuelling growth opportunities in this sector.(Logo: ...
... BASEL, Switzerland, Feb. 10 Syngenta today announced that ... Rice Research Institute (ARRI) of Anhui Academy of Agricultural ... conducting laboratory and field tests of novel gene functions ... optimization in key crops such as corn and soybean. ...
... CHAMPAIGN, Ill. By pushing carbon nanotubes close ... of Illinois have demonstrated a remarkable increase in ... what was previously thought possible., The researchers drove ... carries more electrons down more paths, similar to ...
Cached Biology Technology:Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 2Frost & Sullivan Sees Microdosing as Compelling Advantage for Big Pharma 3Syngenta Enters Into Research Collaboration With Anhui Academy, China 2Syngenta Enters Into Research Collaboration With Anhui Academy, China 3Carbon nanotube avalanche process nearly doubles current 2
(Date:7/25/2014)... time, Spanish researchers have detected an unknown interaction between ... are introduced into a droplet of salt water and ... crystallisation to create biomineralogical biosaline 3D morphologically complex formations, ... bacteria are revived. The discovery was made by chance ... of the Astrobiology journal and may help ...
(Date:7/24/2014)... -- The Geneva Healthcare Suite, an innovative technology platform ... room wait times by an average of 92 minutes ... to a recent study published in the Academic Emergency ... suite to access data from incoming patients, implanted cardiac ... Geneva,s technology platform we have been able to quickly ...
(Date:7/24/2014)... A new study has identified two factors that ... increase the production of highly qualified physics teachers. ... to champion physics teacher education in combination with ... initiatives remain viable. Science, Technology, Engineering and Math ... and the study points the way for institutions ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Creating sustainable STEM teacher preparation programs 2
... Department of Cell Biology and Histology at the University of ... boosted by means of retinoids. It was thought that this ... , Vitamin A, also known as retinol, is ... and as carotene in vegetables that have a yellow-orange colour, ...
... identified a compound that interferes with the pathogenic effects ... development of a new treatment for the disease. , ... that now afflicts 30,000 Americans, with another 150,000 at ... strikes in midlife and causes uncontrolled movements, loss of ...
... Dentistry professor has developed a calcium phosphate-based supplement that ... strength and thickness without the side effects of many ... of Biomaterials and Biomimetics and of Implant Dentistry, presented ... for Dental Research annual meeting on March 9, 2006. ...
Cached Biology News:Retinol for combating leukemia cells 2Retinol for combating leukemia cells 3MIT research holds promise for Huntington's treatment 2New study reveals promising osteoporosis treatment 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... is an enhanced form of Tobacco Etch ... highly active, and significantly more stable than ... AcTEV Protease specifically recognizes a seven amino ... making it useful for removing affinity tags ...
... The Heraeus HERAcell is the ideal ... including development of ova or embryos at ... specifically designed to provide everything needed to ... , , Safe and stable incubation conditions ...
SP6 RNA Polymerase, 50 l, 20 U/l ,Cap Scribe Buffer, 100 l, 5x conc....
Biology Products: